Rentschler Biopharma’s Post

Check out the latest from Circio in this interview with Drug Target Review

Cell and gene therapy has often made headlines due to its nontraditional cost model, but the value of this transformative medicine is often overlooked. ARM's Gene Therapy for Patients and Society (GPS) framework, released at the Biotech Showcase during #JPM24, and CAR-T Therapy for Patients and Society (CAR-PS) framework, released last month, demonstrate how these advanced medicines are poised to provide incredible value. Unpack both value frameworks on our website here: https://lnkd.in/eX2TJiYf

Important aspects of plasmid DNA purity are explained in the new article "Assessing pDNA Purity For Cell & Gene Therapies" by our senior analytical consultant Brian Glass. The application of conventional development methods to the difficulties encountered in producing gene therapy products is examined in this article. Brian highlights the upcoming USP 1040 chapter and offers advice on developing successful control measures for plasmid DNA, a crucial building block in the industry. https://hubs.ly/Q02zMqzM0

Gain insights into the current top challenges in cell and gene therapy and their solutions from Catherine BUCHERE at this year's ESACT. Learn more about Sartorius cell and gene therapy solutions: https://sar.to/0i1cj #SimplifyingProgress #InThisTogether #AdvancedTherapies #CellandGeneTherapy #ESACT #ESACT2024

Gain insights on our take on how we solve three main challenges in advancing cell and gene therapies to clinic. Join Qian(Sarah) Li, PhD, EMBA to learn about how #plasmid DNA serves essential roles as critical materials for cell and gene therapy applications and various key considerations including emerging methods for yield improvement, characterization and quality control. #celltherapy #genetherapy

💡Is Charles River Laboratories the right #CDMO partner for you? ➡ Supported the development of 86% of #FDA approved drugs over last 5 years ➡ Supported the development of 11 FDA approved #cellandgene therapies ➡ Integrated platform and service portfolio Incl. #Research, #Discovery, #Safety, #Testing and #Regulatory ➡ 30+ years of integrated #CGT testing and manufacturing capabilities Incl. #plasmid and #viralvector ➡ Founded in 1947 #science #research #lifesciences #biotechnology #scienceandtechnology #genetherapy

Owen Smith, Partner, sat down with Megan Thomas from Drug Discovery World to discuss 4BIO’s investment strategies and future trends in cell and gene therapy: https://lnkd.in/eaSTRWnh Key topics discussed include: ✅The promise of AAV gene therapies in non-renewing tissues and cell therapies in haematology ✅The challenges that the cell and gene therapy sector is experiencing and working to overcome ✅Regulatory and reimbursement complexities, especially in the EU #4BIO #Interview #Podcast #VC #AdvancedTherapies 

Our Accelerating Science Cell & Gene Therapy Feature is now live, showcasing lab product reviews by scientists like you. Explore top reviews on key technologies from gene editing to manufacturing. #celltherapy #genetherapy #sciencecommunication #reviews #labproducts #geneediting

Excited to share a new article on commercial sustainability of Cell and Gene Therapies I co-authored with Marie-Lyn Horlacher-Hecht Dr. Oliver Eitelwein. CGTs have the potential to revolutionize the treatment landscape and cure previously incurable diseases. The market for these therapies is expected to grow at a compound annual growth rate of 46% over the next five years, reaching a total global market size of nearly $37 billion. However, some challenges must be addressed for these therapies to be commercially viable. How to navigate the path towards unlocking the commercial viability of groundbreaking cell and gene therapies here > https://owy.mn/3QPj9Vt #OWHealth

📖Read the full article: https://lnkd.in/gHvWvzKv Dive into the complexities of AAV gene therapy with insights from Chelsea Pratt, PhD, and Marwan A Alsarraj, MS from Bio-Rad Laboratories! Discover the key challenges in rAAV vector design and bioprocessing in this Labcompare article. ➡️Explore more on gene therapy development and manufacturing here: https://lnkd.in/gWkDyim8 #GeneTherapy #Biopharma #AAV